Results 11 to 20 of about 4,122,734 (351)

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.

New England Journal of Medicine, 2021
BACKGROUND Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33.
M. Wechsler, M. K. Ruddy, I. Pavord, E. Israel, K. Rabe, L. Ford, J. Maspero, R. Abdulai, Chih-Chi Hu, R. Martincova, A. Jessel, M. Nivens, N. Amin, D. Weinreich, G. Yancopoulos, H. Goulaouic   +15 more
semanticscholar   +3 more sources

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.

New England Journal of Medicine, 2021
BACKGROUND Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for the treatment of adults and adolescents with asthma as well
L. Bacharier, J. Maspero, C. Katelaris, A. Fiocchi, R. Gagnon, I. de Mir, N. Jain, L. Sher, X. Mao, Dongfang Liu, Yi Zhang, Asif H Khan, U. Kapoor, F. A. Khokhar, P. Rowe, Y. Deniz, M. Ruddy, E. Laws, N. Patel, D. Weinreich, G. Yancopoulos, N. Amin, L. Mannent, D. Lederer, M. Hardin   +24 more
semanticscholar   +3 more sources

Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma

New England Journal of Medicine, 2018
BACKGROUND Dupilumab is a fully human anti–interleukin‐4 receptor α monoclonal antibody that blocks both interleukin‐4 and interleukin‐13 signaling. Its effectiveness in reducing oral glucocorticoid use in patients with severe asthma while maintaining ...
K. Rabe, Parameswaran Nair, G. Brusselle, J. Maspero, M. Castro, L. Sher, Hongjie Zhu, J. Hamilton, B. Swanson, A. Khan, J. Chao, H. Staudinger, G. Pirozzi, C. Antoni, N. Amin, M. Ruddy, B. Akinlade, N. Graham, N. Stahl, G. Yancopoulos, A. Teper   +20 more
semanticscholar   +3 more sources

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

New England Journal of Medicine, 2021
BACKGROUND Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma.
A. Menzies-Gow, J. Corren, A. Bourdin, G. Chupp, E. Israel, M. Wechsler, C. Brightling, J. Griffiths, A. Hellqvist, K. Bowen, P. Kaur, G. Almqvist, S. Ponnarambil, G. Colice   +13 more
semanticscholar   +3 more sources

Biologic Therapies for Severe Asthma.

New England Journal of Medicine, 2022
G. Brusselle, G. Koppelman
semanticscholar   +3 more sources

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

New England Journal of Medicine, 2017
Parameswaran Nair, S. Wenzel, K. Rabe, A. Bourdin, N. Lugogo, P. Kuna, P. Barker, Stephanie Sproule, S. Ponnarambil, M. Goldman   +9 more
semanticscholar   +3 more sources

Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort.

Chest, 2021
BACKGROUND Phenotypic characteristics of eosinophilic and non-eosinophilic asthma patients are not well-characterized in global, real life severe asthma cohorts.
L. Heaney, L. A. Pérez de Llano, M. Al‐Ahmad, V. Backer, J. Busby, G. Canonica, G. Christoff, B. Cosío, J. FitzGerald, E. Heffler, T. Iwanaga, D. Jackson, A. Menzies-Gow, N. Papadopoulos, A. Papaioannou, P. Pfeffer, Todor A Popov, C. Porsbjerg, C. Rhee, M. Sadatsafavi, Y. Tohda, E. Wang, M. Wechsler, M. Alacqua, A. Altraja, L. Bjermer, U. Björnsdóttir, A. Bourdin, G. Brusselle, R. Buhl, R. Costello, M. Hew, M. K. Siyue, S. Lehmann, L. Lehtimäki, M. Peters, C. Taillé, C. Taube, T. Tran, J. Zangrilli, L. Bulathsinhala, V. Carter, I. Chaudhry, N. Eleangovan, N. Hosseini, M. Kerkhof, R. Murray, C. Price, D. Price   +48 more
semanticscholar   +1 more source

A feasibility randomised controlled trial of Novel Activity Management in severe ASthma-Tailored Exercise (NAMASTE): yoga and mindfulness

BMC Pulmonary Medicine, 2021
Background Physical inactivity is common in severe asthma and associated with poor health outcomes. New approaches are needed to address physical inactivity in this group.
Sarah A. Hiles, Paola D. Urroz, Peter G. Gibson, Adam Bogdanovs, Vanessa M. McDonald   +4 more
doaj   +1 more source

Use of the complex of models of regression for analysis of the factors that determine the severity of bronchial asthma [PDF]

, 2020
Background: According to an International Study of Asthma and Allergies in Childhood (ISAAC), the prevalence of asthma in children of 6-7 years old has increased by 10%, and at the age of 13-14 years by 16% over the last decade.
Kozhyna, Olga S., Pihnastyi, O. M.
core   +2 more sources

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Journal of Asthma and Allergy, 2022
Introduction International registries provide opportunities to describe use of biologics for treating severe asthma in current clinical practice.
A. Menzies-Gow, C. McBrien, B. Unni, C. Porsbjerg, M. Al‐Ahmad, C. Ambrose, K. Dahl Assing, A. von Bülow, J. Busby, B. Cosío, J. FitzGerald, E. Garcia Gil, S. Hansen, Liam G aHeaney, M. Hew, D. Jackson, M. Kallieri, S. Loukides, N. Lugogo, A. Papaioannou, D. Larenas-Linnemann, W. Moore, L. Perez-de-Llano, L. Rasmussen, J. Schmid, Salman Siddiqui, M. Alacqua, T. Tran, C. Suppli Ulrik, J. Upham, E. Wang, L. Bulathsinhala, V. Carter, I. Chaudhry, N. Eleangovan, R. Murray, C. Price, D. Price   +37 more
semanticscholar   +1 more source